Literature DB >> 2241419

The effects of a new cholinolytic--8018--and its optical isomers on the central muscarinic and nicotinic receptors.

W Z Niu1, D L Zhao, C G Liu.   

Abstract

3-(2'-phenyl-2'-cyclopentyl-2'-hydroxyl-ethoxy)quinuclidine (8018), a new cholinolytic, is a racemic tertiary amine with two chiral carbonic atoms. It has 4 optical isomers whose absolute configurations are RR', SR', RS' and SS'. These compounds showed potent pharmacological activity, blocking both central muscarinic and nicotinic receptors. Central muscarinic receptors, rather than nicotinic receptors, have a stereoselective specificity to these compounds. The R configuration of both substituted alkoxyl and alkalinic alcohol parts is more suitable to the stereostructure of the binding site of muscarinic receptors than the S configuration. These compounds can prevent soman-induced electroencephalographic seizures in rats by both their central M- and N-cholinolytic actions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2241419

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Targeting cholinesterase inhibitor poisoning with a novel blocker against both nicotinic and muscarinic receptors.

Authors:  Wangqian Luo; Xulin Ge; Wenyu Cui; Hai Wang
Journal:  Neurotox Res       Date:  2009-10-15       Impact factor: 3.911

2.  Effects of penehyclidine hydrochloride in small intestinal damage caused by limb ischemia-reperfusion.

Authors:  Yan Zhang; Yu-Fang Leng; Xing Xue; Yue Zhang; Tao Wang; Yu-Qing Kang
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

Review 3.  Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.

Authors:  Hong-Tao Xiao; Zhi Liao; Rong-Sheng Tong
Journal:  Drug Des Devel Ther       Date:  2012-11-01       Impact factor: 4.162

4.  A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1.

Authors:  Nan Hua; Xiaoli Wei; Xiaoyan Liu; Xiaoyun Ma; Xinhua He; Rengong Zhuo; Zhe Zhao; Liyun Wang; Haitao Yan; Bohua Zhong; Jianquan Zheng
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.